Hims & Hers Healths 261B Volume Ranks 36th Amid Legal Storm Over Novo Nordisk Partnership Termination

On July 31, 2025, Hims & Hers Health (HIMS) traded with a volume of $2.61 billion, a 27.09% decline from the previous day, ranking 36th in market activity. The stock closed with a 0.99% increase.

A securities fraud lawsuit was filed against Hims & Hers Health and senior executives, alleging violations of federal securities laws. The case, pending in the U.S. District Court for the Northern District of California, claims the company misrepresented its partnership with Novo Nordisk regarding the sale of Wegovy and compounded semaglutide. The partnership was terminated in June 2025 after Novo Nordisk accused Hims of promoting “illegitimate” drug versions, triggering a 34% drop in Hims’ stock price at the time.

The legal action highlights risks tied to regulatory compliance and corporate governance. While Hims’ shares rebounded modestly in early August, the ongoing litigation and reputational damage could weigh on investor sentiment. The case remains unresolved, with shareholders invited to seek involvement by August 25, 2025.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day yielded a 166.71% return from 2022 to July 30, 2025, significantly outperforming the benchmark return of 29.18%. This approach generated an excess return of 137.53%, underscoring its effectiveness in capturing momentum-driven market shifts through high-liquidity assets.